Obesity Drug Costs: Limited-Time Use, Then Shift To Cheaper Maintenance Floated By Sen. Cassidy
Executive Summary
Sen. Bill Cassidy and an obesity advocacy group suggest studies test whether obesity patients could be switched to a cheaper maintenance medicine or diet after their initial weight loss on GLP-1s. Approval of Lilly’s Zepbound is a reminder of the expected surge in utilization for the class.